{"id":"W2978011912","doi":"10.1002/cncr.32532","title":"Patient‐reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose‐escalation study 1108","year":2019,"lang":"en","type":"article","venue":"Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":16,"is_retracted":false,"has_abstract":true,"ca_institutions":"Ottawa Hospital; Princess Margaret Cancer Centre","funders":"AstraZeneca","keywords":"Medicine; Durvalumab; Quality of life (healthcare); Internal medicine; Bladder cancer; Cancer; Metastatic Urothelial Carcinoma; Oncology; Performance status; Urothelial carcinoma; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001430409,0.0005540607,0.001410147,0.0001927703,0.000208211,0.0006042969,0.0004270943,0.0005902146,0.0008865378],"category_scores_gemma":[0.0007842451,0.0002250296,0.0007405554,0.0003194526,0.0002376325,0.0003373837,0.0002113023,0.001074225,0.0002156893],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005493841,"about_ca_system_score_gemma":0.0004402177,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004842429,"about_ca_topic_score_gemma":0.001026159,"domain_scores_codex":[0.999561,0.0001977627,0.00003342533,0.00006423501,0.00008383882,0.00005965793],"domain_scores_gemma":[0.9994593,0.00008857065,0.0001699404,0.00004406169,0.00004911787,0.0001890695],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4193753,0.02800756,0.4020723,0.0009727073,0.00517666,0.0006086385,0.0005016917,0.002553638,0.03601621,0.0001344224,0.003528822,0.101052],"study_design_scores_gemma":[0.1256373,0.1539064,0.7072377,0.00007274545,0.001922555,0.0008520627,0.0001258204,0.00323346,0.004079234,0.0001372359,0.002740697,0.00005473578],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9983863,0.0007844255,0.00006702361,0.00006810025,0.000009592977,0.0001285204,0.0002765991,0.000009117231,0.0002702935],"genre_scores_gemma":[0.997952,0.0003016953,0.0002574929,0.0001580674,0.00002322881,0.0002085161,0.000802448,0.000003112252,0.0002933549],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001430409,"threshold_uncertainty_score":0.007564783,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01074326363061002,"score_gpt":0.2748826430952949,"score_spread":0.2641393794646849,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}